SEC Form 4 · accession 0001144204-16-125866
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Shapiro
Officer — CMO and EVP - Development
Period of report
Sep 26, 2016
Accepted (ET)
Sep 28, 2016 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 26, 2016 | S | 2,659 | $164.7601 | D | 45,732 | D | |
| Common Stock | Sep 26, 2016 | S | 886 | $166.03 | D | 44,846 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person.
- F2This transaction was executed in multiple trades at prices ranging from $164.5201 to $165.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.